Ikaria Australia

Kew, Australia Founded: 2010 • Age: 16 yrs Acquired By Mallinckrodt Pharmaceuticals
Developer of drug delivery system for treating cardiovascular disorders
Request Access

About Ikaria Australia

Ikaria Australia is a company based in Kew (Australia) founded in 2010 was acquired by Mallinckrodt Pharmaceuticals in April 2015.. Ikaria Australia offers products and services including INOmax Cylinders, INOmax Consumables, THERAKOS Kits, and UVADEX. Ikaria Australia operates in a competitive market with competitors including MannKind Corp, Impel NeuroPharma, Alexza, OptiNose and Qnovia, among others.

  • Headquarter Kew, Australia
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
  • Legal Name Ikaria Aust Pty Ltd
Operational Areas
Healthcare → Pharmaceuticals & Therapeutics
Key Metrics
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of Ikaria Australia

Ikaria Australia offers a comprehensive portfolio of products and services, including INOmax Cylinders, INOmax Consumables, THERAKOS Kits, and UVADEX. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.

Primary

Inhalation therapy system for respiratory support in healthcare.

Components for INOmax systems to aid patient treatment.

Photopheresis kits for treating immune disorders.

Drug used in photopheresis procedures for medical applications.

Funding Insights of Ikaria Australia

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Ikaria Australia

Ikaria Australia has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Mallinckrodt Pharmaceuticals. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Specialty pharmaceutical products and diagnostic imaging agents are manufactured.
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Ikaria Australia

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Ikaria Australia

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Ikaria Australia Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Ikaria Australia

Ikaria Australia operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as MannKind Corp, Impel NeuroPharma, Alexza, OptiNose and Qnovia, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Developer of small-molecule drugs
domain founded_year HQ Location
Intranasal delivery technology for CNS diseases is developed.
domain founded_year HQ Location
Developer of products for the treatment of acute and intermittent conditions
domain founded_year HQ Location
Developer of smart devices for nasal drug delivery
domain founded_year HQ Location
Inhaled drug delivery devices are developed for pharmaceuticals.
domain founded_year HQ Location
Therapeutics for cardiopulmonary diseases are developed using inhaled therapies.
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Ikaria Australia

Frequently Asked Questions about Ikaria Australia

When was Ikaria Australia founded?

Ikaria Australia was founded in 2010.

Where is Ikaria Australia located?

Ikaria Australia is headquartered in Kew, Australia. It is registered at Kew, Victoria, Australia.

What does Ikaria Australia do?

Ikaria is a part of Mallinckrodt Pharmaceuticals. They are developing a drug delivery system for treating congestive heart failure and acute myocardial infarction. Their lead candidate INOMAX which is a nitric oxide inhalation, for treating bronchopulmonary dysplasia (BPD) in premature infants, pulmonary arterial hypertension (PAH), and chronic obstructive pulmonary disease (COPD).

Who are the top competitors of Ikaria Australia?

Ikaria Australia's top competitors include MannKind Corp, OptiNose and Impel NeuroPharma.

What products or services does Ikaria Australia offer?

Ikaria Australia offers INOmax Cylinders, INOmax Consumables, THERAKOS Kits, and UVADEX.

Who are Ikaria Australia's investors?

Ikaria Australia has 1 investor. Key investors include Mallinckrodt Pharmaceuticals.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available